Cidofovir induces an increase in levels of low-risk and high-risk HPV E6

Jarrod Homer, Adam J. Donne, Lynne Hampson, Xiaotong T. He, Michael P. Rothera, Jarrod J. Homer, Ian N. Hampson

    Research output: Contribution to journalArticlepeer-review


    Background. Cidofovir is a nucleoside analogue that is used off-license to treat recurrent respiratory papillomatosis (RRP) caused by HPV6/11. However, the effect of this drug upon low-risk HPV 6/11 gene expression is unknown. Methods. The expression of E6 was evaluated by RT-PCR in HPV-ve C33A cervical carcinoma cells stably transfected with both low- and high-risk HPV E6 cDNA's and in SiHa (HPV16+ve) cervical carcinoma cells after treatment with 2 doses and durations of exposure to cidofovir. Results. Compared to the vector only transcript, E6 RNA levels showed an 8-fold increase in low-risk and 20-fold increase in high-risk E6-expressing cells. High-risk E6 protein levels were also detected by Western blot in cidofovir-treated C33A Type16 E6-transfected cells. Conclusion. These data may indicate a potential rationale for increased risk of genetic instability and thus transformation due to drug-induced increase in the level of E6. © 2009 Wiley Periodicals, Inc.
    Original languageEnglish
    Pages (from-to)893-901
    Number of pages8
    JournalHead and Neck
    Issue number7
    Publication statusPublished - Jul 2009


    • Cidofovir
    • HPV E6
    • HPV16
    • HPV6
    • Respiratory papillomatosis


    Dive into the research topics of 'Cidofovir induces an increase in levels of low-risk and high-risk HPV E6'. Together they form a unique fingerprint.

    Cite this